Local and systemic immune responses during rhBMP-2 mediated bone regeneration are dose-dependent in rat model of critical-sized bone defect healing.
Bone morphogenetic proteins (BMPs) are among the most potent clinical therapeutics for promoting bone regeneration, yet their use is limited by potential adverse events such as heterotopic bone formation, osteolysis, and soft tissue inflammation. Sustained release delivery systems may reduce the minimum effective BMP d...